Hemogenyx Pharmaceuticals(OTCPK:HOPHF)与Cellin Technologies签署意向书,探索其CAR-T细胞疗法在爱沙尼亚的商业化。此次合作为Hemogenyx带来了潜在营收机会,更多协议尚待敲定。

本文地址: http://www.jiaotongmi.com/article/8436.html
文章来源:admin
版权声明:除非特别标注,否则均为本站原创文章,转载时请以链接形式注明文章出处。
2025-11-19admin
2025-11-13admin
2025-11-12admin
2025-11-11admin
2025-11-10admin
2025-11-09admin
2025-11-08admin
2025-11-07admin
2025-11-06admin
2025-11-05admin
2025-09-08admin
2025-09-08admin
2025-09-17admin
2025-09-17admin
2025-09-13admin
2025-09-08admin
2025-09-09admin
2025-09-09admin
2025-09-13admin
2025-09-11admin
2025-09-08admin
2025-09-08admin
2025-09-17admin
2025-09-09admin
2025-09-08admin
2025-09-08admin
2025-09-08admin
2025-09-08admin
2025-09-17admin
2025-09-08admin
扫码二维码
获取最新动态
